Cu64/67 is owned by Clarity (NSW based). SAR-bisPSMA - Next-Generation, Highly Targeted Prostate Cancer Theranostic - Clarity (claritypharmaceuticals.com)
They are not listed, hadn't heard they were planning for ASX listing.
Cu64 has theoretical advantages. With a 12h half life, you can do serial imaging - you get an idea of disease sites the injection gets to after a few hours, then a day later you can see if those sites retained the tracer and potentially even stretch it out to 2 days.
This is useful for estimating dosimetry and the actual radiation dose delivered to sites of disease.
With Ga68 (~1h half life), you cannot assess for retention beyond 3-4h, so even if a disease site takes up the tracer very strongly, it might dissociate after 8 hours and you'd never know. So if you were to administer Lu-177 bound to the ligand, there would only be treatment at the disease site for a short while (ie. may not work).
Same with Zr89 btw (TLX using this for TLX250 cdx, even longer half life at 78h.)
hope that makes senes
- Forums
- ASX - By Stock
- Competition
Cu64/67 is owned by Clarity (NSW based). SAR-bisPSMA -...
-
- There are more pages in this discussion • 230 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$19.19 |
Change
0.780(4.24%) |
Mkt cap ! $6.421B |
Open | High | Low | Value | Volume |
$18.85 | $19.19 | $18.78 | $22.02M | 1.155M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2216 | $19.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.20 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1 | 19.090 |
1 | 10000 | 19.050 |
2 | 10000 | 19.040 |
2 | 1100 | 19.000 |
1 | 1000 | 18.930 |
Price($) | Vol. | No. |
---|---|---|
19.200 | 1000 | 1 |
19.250 | 5000 | 1 |
19.290 | 5000 | 1 |
19.300 | 2172 | 2 |
19.390 | 5000 | 1 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |